ClinicalTrials.Veeva

Menu

Advanced Harmonic Generation Microscopy for Treatment Assessment of Cutaneous Pigmentary Disorder

National Taiwan University logo

National Taiwan University

Status

Completed

Conditions

Solar Lentigo
Nevus Zygomaticus

Treatments

Device: HGM

Study type

Interventional

Funder types

Other

Identifiers

NCT03578315
201612113DINC

Details and patient eligibility

About

In this study, the investigators demonstrated that in vivo THG microscopy can differentiate Solar lentigos (SL), Nevus zygomaticus(NZ) and normal skin based on the optical nature of melanin. This THG-based procedure provides a valuable tool for noninvasive determination of third-order nonlinear susceptibility of melanin within the skin. It can also provide real-time histopathology information for treatment follow-up, without performing an invasive skin biopsy.

Full description

A nonrandomized, controlled, split-face comparative study was conducted to compare the efficacy and safety between quality-switched ruby laser (QSRL) and 532-nm picosecond Nd:YAG laser (532-PSNYL for SL, 1064-PSNYL for NZ) in the treatment of solar lentigo clinically and histologically by harmonic generation microscopy (HGM). After baseline photography and in vivo harmonic generation microscopy (HGM) imaging, QSRL and 532-PSNYL or 1064-PSNYL therapy for solar lentigos and nevus zygomaticus on the left and right side of the face, respectively, were performed for each subject. The subjects underwent follow-up assessment at weeks 3 and 6.

Statistical analysis: All data gathered went through decoding and were analyzed by blinded evaluators using SPSS software (version 20.0; IBM, Armonk, NY). All tests were two-sided. A P value of < .05 was considered to be statistically significant.

Enrollment

50 patients

Sex

All

Ages

20 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

  1. Main inclusion criteria:

  2. Subjects are aged 20 to 85 years at Screening, and can be either sex.

  3. Subjects are Fitzpatrick skin type III or IV.

  4. Subjects must have been diagnosed to have solar lentigos or nevus zygomaticus, which are larger than 4 mm in diameter on both sides of the face.

  5. Main exclusion criteria:

  6. Subjects have previous treatments on the solar lentigos or nevus zygomaticus.

  7. Subjects have a history of adverse reaction to laser treatments, including allergy to topical anesthesia application.

  8. Subjects have a history of chronic inflammatory disorder such as atopic dermatitis on the face.

  9. Subjects are pregnant or breast feeding.

  10. Subjects have frequent sun exposure (≥4 hours per day).

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

50 participants in 2 patient groups

Solar lentigo
Experimental group
Description:
25 Patients with Solar lentigo
Treatment:
Device: HGM
Nevus zygomaticus
Experimental group
Description:
25 Patients with Nevus zygomaticus
Treatment:
Device: HGM

Trial contacts and locations

1

Loading...

Central trial contact

Yi-Hua Liao

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems